{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:30:42Z","timestamp":1787614242980,"version":"build-2736575974"},"reference-count":146,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00588","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T07:16:18Z","timestamp":1745046978000},"page":"e00588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions"],"prefix":"10.1016","volume":"22","author":[{"given":"Gauruv","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.X.","family":"Thebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00588_bib2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1352458519887324","article-title":"Precision medicine in the multiple sclerosis clinic: selecting the right patient for the right treatment","volume":"26","author":"Bose","year":"2020","journal-title":"Multiple Sclerosis Journal [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib4","first-page":"522","volume":"26","author":"Chitnis","year":"2020","journal-title":"A roadmap to precision medicine for multiple sclerosis. Multiple Sclerosis Journal [Internet]"},{"key":"10.1016\/j.neurot.2025.e00588_bib5","article-title":"Serum neurofilament light in MS: the first true blood-based biomarker?","author":"Thebault","year":"2021","journal-title":"Multiple Sclerosis Journal [Internet]"},{"key":"10.1016\/j.neurot.2025.e00588_bib6","article-title":"Serum neurofilament light chain measurement in MS: hurdles to clinical translation","volume":"15","author":"Thebault","year":"2021","journal-title":"Front Neurosci [Internet]"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"SLAS Technol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol [Internet]"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00588_bib9","first-page":"e1641","article-title":"Effect of changes in MS diagnostic criteria over 25 Years on time to treatment and prognosis in patients with clinically isolated syndrome","volume":"97","author":"Tintore","year":"2021","journal-title":"Neurology [Internet]"},{"issue":"6578","key":"10.1016\/j.neurot.2025.e00588_bib10","first-page":"296","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science (1979) [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein\u2013Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"7900","key":"10.1016\/j.neurot.2025.e00588_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI101335","article-title":"AN electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins 1","volume":"21","author":"Kabat","year":"1942","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1471-4159.1960.tb13448.x","article-title":"The differential diagnosis of neurological diseases by fractionating electro-PHORETICALLY the CSF \u03b3-GLOBULINS","volume":"6","author":"Lowenthal","year":"1960","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib16","article-title":"The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis","volume":"6","author":"Simonsen","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00588_bib17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/medicina58111512","article-title":"The use of kappa free light chains to diagnose multiple sclerosis","volume":"58","author":"Arneth","year":"2022","journal-title":"Medicina"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200049","article-title":"Kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis","volume":"10","author":"Levraut","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib19","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458508096878","article-title":"Differential diagnosis of suspected multiple sclerosis: a consensus approach","volume":"14","author":"Miller","year":"2008","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.neurot.2025.e00588_bib20","series-title":"2024 revisions of the McDonald criteria presented at ECTRIMS congress; September 18-20, 2024; Copenhagen, Denmark scientific Session 1: new Diagnostic Criteria","article-title":"Revisions of the McDonald criteria","author":"Montalban","year":"2024"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/13524585231219131","article-title":"Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome","volume":"30","author":"Schneider","year":"2024","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00588_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2015.85","article-title":"Aggressive multiple sclerosis: proposed definition and treatment algorithm","volume":"11","author":"Rush","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s00415-017-8487-y","article-title":"Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study","volume":"264","author":"Sartori","year":"2017","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1352458512460605","article-title":"Scoring treatment response in patients with relapsing multiple sclerosis","volume":"19","author":"Sormani","year":"2013","journal-title":"Multiple Sclerosis Journal [Internet]"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00588_bib25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458509104591","article-title":"Measures in the first year of therapy predict the response to interferon \u03b2 in MS","volume":"15","author":"R\u00edo","year":"2009","journal-title":"Multiple Sclerosis Journal [Internet]"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00588_bib26","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ene.14845","article-title":"Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score","volume":"28","author":"Gasperini","year":"2021","journal-title":"Eur J Neurol [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awaa081","article-title":"Early clinical markers of aggressive multiple sclerosis","volume":"143","author":"Malpas","year":"2020","journal-title":"Brain [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ana.26370","article-title":"Early predictors of clinical and MRI outcomes using least absolute Shrinkage and selection operator (LASSO) in multiple sclerosis","volume":"92","author":"Bose","year":"2022","journal-title":"Ann Neurol [Internet]"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib29","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jnnp-2022-329353","article-title":"Younger age at multiple sclerosis onset is associated with worse outcomes at age 50","volume":"93","author":"Bose","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00588_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104695","article-title":"Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes","volume":"74","author":"Bose","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00588_bib31","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann Clin Transl Neurol [Internet]"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/jon.12826","article-title":"MRI lesion state modulates the relationship between serum neurofilament light and age in multiple sclerosis","volume":"31","author":"Rosso","year":"2021","journal-title":"J Neuroimaging [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib33","article-title":"Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS","volume":"8","author":"Lokhande","year":"2022","journal-title":"Mult Scler J Exp Transl Clin [Internet]"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00588_bib34","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acn3.638","article-title":"Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann Clin Transl Neurol [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib35","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci Rep [Internet]"},{"key":"10.1016\/j.neurot.2025.e00588_bib36","article-title":"Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?","volume":"10","author":"Abdelhak","year":"2019","journal-title":"Front Neurol [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib39","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurology - Neuroimmunology Neuroinflammation [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis","volume":"81","author":"Cross","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75290-8","article-title":"The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis","volume":"14","author":"Thebault","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Treatment optimization in MS: Canadian MS Working Group updated recommendations","volume":"40","author":"Freedman","year":"2013","journal-title":"Can J Neurol Sci [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib45","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00415-022-11480-6","article-title":"Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders","volume":"270","author":"Dinoto","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00588_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103922","article-title":"Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL","volume":"63","author":"Gawde","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00588_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s10194-023-01674-2","article-title":"Serum neurofilament light chain levels in migraine patients: a monocentric case\u2013control study in China","volume":"24","author":"Fang","year":"2023","journal-title":"J Headache Pain"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/acn3.51060","article-title":"Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis","volume":"7","author":"Rosso","year":"2020","journal-title":"Ann Clin Transl Neurol [Internet]"},{"issue":"11\u201312","key":"10.1016\/j.neurot.2025.e00588_bib50","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1177\/13524585231198751","article-title":"Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis","volume":"29","author":"Bose","year":"2023","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib51","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci Rep [Internet]"},{"key":"10.1016\/j.neurot.2025.e00588_bib52","article-title":"High or increasing serum NfL is predictive of impending multiple sclerosis relapses","volume":"59","author":"Thebault","year":"2022","journal-title":"Mult Scler Relat Disord [Internet]"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00588_bib53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/biomedicines8110523","article-title":"Blood neurofilament light chain: the neurologist's troponin?","volume":"8","author":"Thebault","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurot.2025.e00588_bib54","article-title":"Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials","volume":"13","author":"Ziemssen","year":"2022","journal-title":"Front Immunol [Internet]"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00588_bib55","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology [Internet]"},{"key":"10.1016\/j.neurot.2025.e00588_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"issue":"10044","key":"10.1016\/j.neurot.2025.e00588_bib57","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib58","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/acn3.51045","article-title":"Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis","volume":"7","author":"Thebault","year":"2020","journal-title":"Ann Clin Transl Neurol [Internet]"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00588_bib59","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib60","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200167","article-title":"Increasing neurofilament and glial fibrillary acidic protein after treatment discontinuation predicts multiple sclerosis disease activity","volume":"10","author":"Bose","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00588_bib61","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00588_bib62","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","article-title":"Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study","volume":"17","author":"Kessler","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib63","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000727","article-title":"Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD","volume":"7","author":"Jitprapaikulsan","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00588_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116671","article-title":"Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)","volume":"410","author":"Akaishi","year":"2020","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib65","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/cen3.12664","article-title":"Anti-aquaporin-4 positive-to-negative seroconversion in Latin American patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"12","author":"Zabala-\u00c1ngeles","year":"2021","journal-title":"Clin Exp Neuroimmunol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib66","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00588_bib69","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: a comparative study","volume":"267","author":"Gastaldi","year":"2020","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib70","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007828","article-title":"Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology","volume":"93","author":"Sechi","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib71","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti\u2013myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib72","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00588_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurot.2025.e00588_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122909","article-title":"Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"458","author":"Molazadeh","year":"2024","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib75","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(23)00210-7","article-title":"Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study","volume":"22","author":"Abdelhak","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad063","article-title":"Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children","volume":"5","author":"Horellou","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2025.e00588_bib77","first-page":"12","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib78","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00588_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00588_bib80","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/jnnp-2018-320287","article-title":"Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders","volume":"90","author":"Mariotto","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00588_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104704","article-title":"High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases","volume":"74","author":"Ziaei","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00588_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109761","article-title":"Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS\/MS and Simoa","volume":"116","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib83","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jnc.15549","article-title":"Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: correlation with relapses and seizures","volume":"160","author":"Luo","year":"2022","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurot.2025.e00588_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.754518","article-title":"Serum neurofilament light chain levels and myelin oligodendrocyte glycoprotein antibodies in pediatric acquired demyelinating syndromes","volume":"12","author":"Simone","year":"2021","journal-title":"Front Neurol"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00588_bib85","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib86","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/13524585211063756","article-title":"Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: longitudinal assessment of serum neurofilament light chain","volume":"28","author":"Hyun","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00588_bib87","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00415-019-09306-z","article-title":"Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis","volume":"266","author":"Mariotto","year":"2019","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib88","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib89","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1038\/s41598-023-32748-5","article-title":"Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00588_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105093","article-title":"Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis","volume":"80","author":"Molazadeh","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib91","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/13524585211024978","article-title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Kim","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib92","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000965","article-title":"Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder","volume":"8","author":"Hyun","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib94","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/jnc.15478","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study","volume":"159","author":"Liu","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurot.2025.e00588_bib95","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054952","article-title":"Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder","volume":"14","author":"Zhang","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib96","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00588_bib97","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00588_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2019.06.035","article-title":"The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"35","author":"Qin","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib99","article-title":"Different complement activation patterns following C5 cleavage in MOGAD and AQP4-IgG+NMOSD","volume":"11","author":"Kaneko","year":"2024","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib100","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00588_bib101","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMoa1816721","article-title":"Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis","volume":"381","author":"Mandel-Brehm","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib104","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00588_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719432","article-title":"CSF-neurofilament light chain levels in NMDAR and LGI1 encephalitis: a National cohort study","volume":"12","author":"Nissen","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib106","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.3390\/ijms24097960","article-title":"Autoimmune neuroinflammatory diseases: role of interleukins","volume":"24","author":"Khan","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib107","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib108","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001084","article-title":"Neurosarcoidosis","volume":"8","author":"Bradshaw","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib109","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s10753-016-0441-0","article-title":"Activated CD4+ and CD8+ T cell proportions in multiple sclerosis patients","volume":"39","author":"Arneth","year":"2016","journal-title":"Inflammation"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib110","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of Natalizumab-treated patients with multiple sclerosis","volume":"63","author":"St\u00fcve","year":"2006","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib111","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/ene.13975","article-title":"The cerebrospinal fluid <scp>CD<\/scp> 4\/<scp>CD<\/scp> 8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study","volume":"26","author":"Chazal","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00588_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.05.020","article-title":"Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis","volume":"285","author":"Bridel","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00588_bib113","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/brainsci11020238","article-title":"Elevated neurofilament light chain in cerebrospinal fluid and plasma reflect inflammatory MRI activity in neurosarcoidosis","volume":"11","author":"Byg","year":"2021","journal-title":"Brain Sci"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223897","article-title":"Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis","volume":"14","author":"Eurelings","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000029511","article-title":"Interleukin-10 secretion by Alveolar macrophages and monocytes in sarcoidosis","volume":"67","author":"Bingisser","year":"2000","journal-title":"Respiration"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib116","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.41299","article-title":"Association of high serum interleukin-6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis","volume":"72","author":"Boyapati","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib117","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/molecules27103194","article-title":"Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases","volume":"27","author":"Rauf","year":"2022","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib118","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006082","article-title":"CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease","volume":"91","author":"Janelidze","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00588_bib119","article-title":"Biomarkers in autoimmune diseases of the central nervous system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib120","first-page":"66","article-title":"Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET","volume":"55","author":"Keijsers","year":"2011","journal-title":"Q J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib121","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(16)30140-5","article-title":"Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis","volume":"15","author":"Morbelli","year":"2016","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00588_bib122","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/ard.62.7.659","article-title":"Clinical value of gallium-67 scintigraphy in assessment of disease activity in Wegener's granulomatosis","volume":"62","author":"Slart","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib123","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00415-020-10290-y","article-title":"Neurofilament light is a biomarker of brain involvement in lupus and primary Sj\u00f6gren\u2019s syndrome","volume":"268","author":"Tjensvoll","year":"2021","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib124","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: a review","volume":"20","author":"Carri\u00f3n-Barber\u00e0","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib126","article-title":"Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review","volume":"8","author":"Molazadeh","year":"2022","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib128","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12883-022-02998-3","article-title":"Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus","volume":"22","author":"Zervides","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurot.2025.e00588_bib129","first-page":"14","article-title":"Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus","author":"Engel","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"American college of rheumatology\/European league against rheumatism classification criteria for primary sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib131","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/acr.24017","article-title":"Incorporation of salivary gland ultrasonography into the American college of rheumatology\/European league against rheumatism criteria for primary Sj\u00f6gren\u2019s syndrome","volume":"72","author":"van Nimwegen","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib132","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-0034-1390391","article-title":"Neurologic complications of systemic lupus erythematosus, sj\u00f6gren syndrome, and rheumatoid arthritis","volume":"34","author":"Bhattacharyya","year":"2014","journal-title":"Semin Neurol"},{"issue":"Suppl 118","key":"10.1016\/j.neurot.2025.e00588_bib133","first-page":"192","article-title":"The kaleidoscope of neurological manifestations in primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Alunno","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00588_bib134","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of Neuro-Beh\u00e7et\u2019s disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib135","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.55730\/1300-0144.5432","article-title":"Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Beh\u00e7et\u2019s disease","volume":"52","author":"Karaaslan","year":"2022","journal-title":"Turk J Med Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib136","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae123","article-title":"Neuro-Beh\u00e7et\u2019s disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis","volume":"219","author":"Zhan","year":"2025","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00588_bib137","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3988\/jcn.2022.0493","article-title":"Inflammatory cerebral amyloid angiopathy: a broad clinical spectrum","volume":"19","author":"de Souza","year":"2023","journal-title":"J Clin Neurol"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00588_bib138","doi-asserted-by":"crossref","first-page":"23727","DOI":"10.18632\/aging.103927","article-title":"Neurofilament light chain predicts risk of recurrence in cerebral amyloid angiopathy-related intracerebral hemorrhage","volume":"12","author":"Cheng","year":"2020","journal-title":"Aging."},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib139","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semarthrit.2014.02.001","article-title":"Amyloid beta-related angiitis\u2014a case report and comprehensive review of literature of 94 cases","volume":"44","author":"Danve","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.neurot.2025.e00588_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on A\u03b2 immunotherapy induced ARIA","volume":"16","author":"Foley","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00588_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000024","article-title":"Defining the role of the MHC in autoimmunity: a review and pooled analysis","volume":"4","author":"Fernando","year":"2008","journal-title":"PLoS Genet"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00588_bib142","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41573-023-00083-z","article-title":"NfL makes regulatory debut as neurodegenerative disease biomarker","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00588_bib143","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.3390\/ijms25105412","article-title":"Multiple sclerosis: from the application of oligoclonal bands to novel potential biomarkers","volume":"25","author":"Maglio","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00588_bib144","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with Frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00588_bib145","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/s41467-024-48602-9","article-title":"Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis","volume":"15","author":"Chitnis","year":"2024","journal-title":"Nat Commun"},{"issue":"7982","key":"10.1016\/j.neurot.2025.e00588_bib146","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","article-title":"Large-scale plasma proteomics comparisons through genetics and disease associations","volume":"622","author":"Eldjarn","year":"2023","journal-title":"Nature"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T12:59:59Z","timestamp":1755089999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000662"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00588","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00588"}}